Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
PrognomiQ
AddedFeb 15, 2024
UpdatedJun 18, 2026
PrognomiQ

PrognomiQ

PrognomiQ delivers accurate, fast proteomic data for early disease detection and treatment solutions.

HQ
San Mateo, CA, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

PrognomiQ is focused on transforming early disease detection and treatment through advanced proteomic technology. The company generates highly accurate, scalable, and fast proteomic data, which is integrated with genomic, metabolomic, and other health information. This multi-omics approach enables the development of first-in-class test products aimed at detecting and treating cancer and other complex diseases at an early stage.

PrognomiQ has made significant strides in leveraging multi-omics data to impact millions of lives by improving the detection and treatment of complex diseases. The company's innovative test products are designed to provide earlier and more precise diagnoses, potentially leading to better patient outcomes. Through its cutting-edge technology and comprehensive data integration, PrognomiQ is positioned as a leader in the field of early disease detection.

PrognomiQ - Similar Companies

SensOmics logo

SensOmics

Epinoma logo

Epinoma

epinoma.com

Freenome logo

Freenome

freenome.com

Predictive Biosciences logo

Predictive Biosciences

Episteme Prognostics logo

Episteme Prognostics

epistemedx.com

Quantgene logo

Quantgene

quantgene.com

Predictive Health Diagnostics Company logo

Predictive Health Diagnostics Company

PrognosDx Health logo

PrognosDx Health

Probius logo

Probius

probius.bio

Sera Prognostics logo

Sera Prognostics

Complete Omics logo

Complete Omics

completeomics.com

Prognos Health logo

Prognos Health

prognoshealth.com

Alamar Biosciences logo

Alamar Biosciences

alamarbio.com

Seer logo

Seer

seer.bio

Applied Proteomics logo

Applied Proteomics

PrognomiQ - Quick Facts

Who are PrognomiQ's competitors?

Companies similar to PrognomiQ include SensOmics, Epinoma, Freenome and Predictive Biosciences.

When was PrognomiQ founded?

PrognomiQ was founded in 2020.

Where is PrognomiQ's headquarters located?

PrognomiQ's headquarters is located in San Mateo, CA, US.

When was PrognomiQ's last funding round?

PrognomiQ's most recent funding round was for $46M (USD) in March 2022.

How much has PrognomiQ raised to-date?

As of Mar 15, 2022, PrognomiQ has raised a total of $101M (USD).

How many employees does PrognomiQ have?

PrognomiQ has 51 employees as of Feb 4, 2024.

PrognomiQ - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • AI
  • Analytics
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Disease Detection
  • Proteomics
Tags
  • Biotech
  • Data Information
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software